[Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy].

Heiligenhaus, A; Tappeiner, Christoph; Walscheid, K; Heinz, C (2016). [Uveitis associated with juvenile idiopathic arthritis : Optimization of immunomodulatory therapy]. Der Ophthalmologe, 113(5), pp. 391-397. Springer 10.1007/s00347-016-0262-4

[img]
Preview
Text
s00347-016-0262-4.pdf - Published Version
Available under License Publisher holds Copyright.

Download (234kB) | Preview

BACKGROUND

Uveitis associated with juvenile idiopathic arthritis (JIA-associated uveitis) is a vision-threatening disorder with a high complication rate. Besides early diagnosis within screening programs an adequate therapy is essential for improvement of the long-term prognosis. Corticosteroid therapy is often insufficient. In addition to conventional immunosuppression, immunomodulatory drugs, so-called biologicals, are novel highly effective treatment modalities.

OBJECTIVE

A systematic search of the literature was carried out for biologicals currently used in the treatment of JIA-associated uveitis.

MATERIAL AND METHODS

Review of current publications, summary of treatment guidelines and discussion of treatment options for therapy refractive patients.

RESULTS

In accordance with the current recommendations tumor necrosis factor (TNF) inhibitors are administered if uveitis inactivity cannot be achieved with topical corticosteroids and in the next stage with immunosuppressants (methotrexate preferred). According to the currently available data adalimumab is then preferred. When the effectiveness of TNF inhibitors ceases during long-term administration and/or recurrences, other biological response modifiers are attractive treatment options (e. g. lymphocyte inhibitors or specific receptor antagonists).

CONCLUSION

The TNF inhibitors are of major importance for the treatment of JIA-associated uveitis. Prospective studies and registries would be desirable in order to be able to compare the value of TNF inhibitors and other biologicals and for optimization of treatment recommendations.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Tappeiner, Christoph

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1433-0423

Publisher:

Springer

Language:

German

Submitter:

Christoph Tappeiner

Date Deposited:

18 Apr 2019 14:09

Last Modified:

05 Dec 2022 15:01

Publisher DOI:

10.1007/s00347-016-0262-4

PubMed ID:

27142035

Uncontrolled Keywords:

Biologicals Complications Immunosuppressants TNF inhibitors Visual acuity

BORIS DOI:

10.48350/93129

URI:

https://boris.unibe.ch/id/eprint/93129

Actions (login required)

Edit item Edit item
Provide Feedback